Related Experiment Video

Updated: May 23, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Intercepting neoplastic progression in lung malignancies via the beta adrenergic (β-AR) pathway: implications for

Hussein A N Al-Wadei1, Mohammad F Ullah, Mohammed H Al-Wadei

  • 1Experimental Oncology Laboratory, Department of Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, TN 37996, USA. halwadei@utk.edu

Pharmacological Research
|April 11, 2012
PubMed

Insights

The beta-adrenergic signaling pathway promotes cancer growth and metastasis. GABAergic signaling counteracts these effects, offering new therapeutic targets for cancer intervention.

Area of Science:

  • Oncology
  • Neurobiology
  • Molecular Biology

Background:

  • Cancer progression involves complex, incompletely understood signaling pathways.
  • Cellular signaling imbalances are critical drivers of neoplastic processes.
  • The fight-or-flight response regulator, beta-adrenergic signaling, is implicated in cancer.

Purpose of the Study:

  • To review the role of beta-adrenergic signaling in cancer growth and progression.
  • To examine the contribution of this network to human malignancies.
  • To identify potential chemotherapeutic targets within this pathway.

Main Methods:

  • Review of in vitro and in vivo cancer models.
  • Analysis of experiments from the authors' laboratory and others.
  • Examination of molecular mechanisms including adenylyl cyclase/cAMP/PKA/CREB and EGFR pathways.

Main Results:

  • Beta-adrenergic receptor stimulation promotes cancer by activating pro-oncogenic signaling.
  • This pathway facilitates cancer hallmarks like evasion of apoptosis, invasion, angiogenesis, and metastasis.
  • GABAergic signaling antagonizes beta-adrenergic cascade, inhibiting pro-oncogenic effects.

Conclusions:

  • Neurobiological signals, like beta-adrenergic and GABAergic pathways, regulate cancer cell growth.
  • This expands therapeutic possibilities for pharmacological interventions in cancer treatment.
  • Targeting these neurobiological pathways may offer novel chemotherapeutic strategies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: